MedTrace Logo

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

NCT06394713 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-05-01

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.

Conditions

  • Advanced Malignant Neoplasm

Interventions

DRUG

QLF31907

intravenous administration, once every 3 weeks

DRUG

Irinotecan

intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks

DRUG

Docetaxel

intravenous administration, 75mg/m2, d1, every 3 weeks

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2025-06-15
Completion
2026-12-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06394713 on ClinicalTrials.gov